Those Who Invested in Exelixis (NASDAQ:EXEL) Three Years Ago Are up 127%

Simply Wall StNov 29 21:03

RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)

TipRanksNov 28 09:48 · Ratings

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

BusinesswireNov 28 05:05

ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion

Zacks Nov 27 23:35

FDA to Review Exelixis' Application to Expand Use of Cancer Drug

WSJNov 27 06:58

Exelixis Says US FDA Will Review Supplemental NDA for Prospective Treatment for Pancreatic Tumors in March

MT NewswiresNov 27 06:37